Citations

Mayo Clinic

Showing 10 of 108599 citations.

Gravidez não planejada no Brasil: estudo nacional em oito hospitais universitários
Nilson, Tainá Vieira , Amato, Angélica Amorim , Resende, Ceres Nunes , Primo, Walquíria Quida Salles Pereira , Nomura, Roseli Mieko Yamamoto , Costa, Maria Laura , Opperman, Maria Lúcia, Brock, M. , Trapani, Alberto , Damásio, Lia Cruz Vaz da Costa , Reis, Nadia , Borges, Vera Therezinha Medeiros , Araújo, Ana Cristina Pinheiro Fernandes de , Opperman, Maria Lucia , Brock, Marianna Facchinetti , Trapani, Alberto , Borges, Vera , Araujo, Ana Cristina Pinheiro Fernandes de , Ruano, Rodrigo , Zaconeta, Alberto , Nomura, Roseli , Damasio, Lia , Nilson, Taína Vieira , Ruano, Rodrigo

Revista de Saúde Pública | August 2, 2023 | Volume: 57 | Issue: 1 | Pages: 35

10.11606/s1518-8787.2023057004449 | PMID 37377331 Get It

OBJETIVO: Estimar a prevalência de gestação não planejada (GNP) em oito hospitais públicos universitários, distribuídos nas cinco regiões que compõem o Brasil. MÉTODOS: Análise secundária de um estudo transversal multicêntrico nacional, realizado em oito hospitais universitários públicos, entre 1º de junho e 31 de agosto de 2020, no Brasil. Amostra por conveniência incluindo mulheres que deram à luz em período de sessenta dias consecutivos e atenderam aos seguintes critérios: maiores de 18 anos; idade gestacional acima de 36 semanas no parto; com recém-nascido único e vivo, sem malformações. RESULTADOS: Amostra composta por 1.120 puérperas, das quais 756 (67,5%) declararam que a gravidez não tinha sido programada. A mediana da prevalência de GNP foi de 59,7%. Observou-se diferença significativa na prevalência de GNP entre os hospitais: Campinas (54,8%), Porto Alegre (58,2%), Florianópolis (59%), Teresina (61,2%), Brasília (64,3%), São Paulo (64,6%), Campo Grande (73,9%) e Manaus (95,3%) (p < 0,001). Foram fatores significativamente associados a GNP a idade materna, cor negra, menor renda familiar, maior número de filhos, maior número de pessoas convivendo em casa e não ter parceiro. CONCLUSÃO: na amostra estudada, cerca de dois terços das gestações foram declaradas como não programadas. A prevalência de gestação não planejada teve relação com fatores sociais e demográficos e variou significativamente entre os hospitais universitários avaliados.
The New NCI Precision Medicine Trials
Harris, Lyndsay N. , Blanke, Charles D. , Erba, Harry P. , Ford, James M. , Gray, Robert J. , LeBlanc, Michael , Hu‐Lieskovan, Siwen , Litzow, Mark R. , Luger, Selina M. , Meric‐Bernstam, Funda , O’Dwyer, Peter J. , Politi, Katerina , Shepherd, Lois E. , Allegra, Carmen J. , Korde, Larissa A. , Little, Richard F. , Moscow, Jeffrey A. , Thurin, Magdalena , Doroshow, James H. , LeBlanc, Michael L , Othus, Megan , Politi, Katerina , Shepherd, LE , Allegra, Carmen J , Chen, Helen X , Ivy, S. Percy , Korde, Larissa A , Little, Richard F , McShane, Lisa M. , Moscow, Jeffrey A , Patton, David R , Thurin, Magdalena , Yee, Laura M , Doroshow, James H , Erba, Harry Paul , Meric-Bernstam, Funda , Gray, Robert J , Patton, David R.

Clinical Cancer Research | August 2, 2023 | Volume: 29 | Issue: 23 | Pages: 4728-4732

10.1158/1078-0432.ccr-23-0917 | PMID 37531248 Get It

Abstract Basket, umbrella, and platform trial designs (master protocols) have emerged over the last decade to study precision medicine approaches in oncology. First-generation trials like NCI-MATCH (Molecular Analysis for Therapy Choice) have proven the principle that studying targeted therapies on a large scale is feasible both from the laboratory and clinical perspectives. However, single-agent targeted therapies have shown limited ability to control metastatic disease, despite careful matching of drug to target. As such, newer approaches employing combinations of targeted therapy, or targeted therapy with standard therapies, need to be considered. The NCI has recently embarked on three second-generation precision medicine trials to address this need: ComboMATCH, iMATCH, and myeloMATCH. The design of these trials and necessary infrastructure are discussed in the following perspective.
Plasma exchange for acute and acute-on-chronic liver failure: A systematic review and meta-analysis
Mohamed, Mouhand , Shaear, Mohammad , Nayfeh, Tarek , Mhanna, Mohammed , Srour, Omar, Nawras, Mohamad , Mentrose, Jonathan A., Assaly, Ragheb , Kubal, Chandrashekhar A. , Ghabril, Marwan , Patidar, Kavish R. , Kubal, Chandrashekhar A , Ghabril, Marwan S , Hernaez, Ruben , Mohamed, Mouhand F H , Nayfeh, Tarek , Patidar, Kavish R , Beran, Azizullah

Liver Transplantation | August 2, 2023 | Volume: 30 | Issue: 2 | Pages: 127-141

10.1097/lvt.0000000000000231 | PMID 37530812 Get It

Plasma exchange (PE) is a promising therapeutic option in patients with acute liver failure (ALF) and acute-on-chronic liver failure (ACLF). However, the impact of PE on patient survival in these syndromes is unclear. We aimed to systematically investigate the use of PE in patients with ALF and ACLF compared with standard medical therapy (SMT). We searched PubMed/Embase/Cochrane databases to include all studies comparing PE versus SMT for patients ≥ 18 years of age with ALF and ACLF. Pooled risk ratios (RR) with corresponding 95% CIs were calculated by the Mantel-Haenszel method within a random-effect model. The primary outcome was 30-day survival for ACLF and ALF. Secondary outcomes were overall and 90-day survival for ALF and ACLF, respectively. Five studies, including 343 ALF patients (n = 174 PE vs. n = 169 SMT), and 20 studies, including 5,705 ACLF patients (n = 2,856 PE vs. n = 2,849 SMT), were analyzed. Compared with SMT, PE was significantly associated with higher 30-day (RR 1.41, 95% CI 1.06–1.87, p = 0.02) and overall (RR 1.35, 95% CI 1.12–1.63, p = 0.002) survival in ALF patients. In ACLF, PE was also significantly associated with higher 30-day (RR 1.36, 95% CI 1.22–1.52, p < 0.001) and 90-day (RR 1.21, 95% CI 1.10–1.34, p < 0.001) survival. On subgroup analysis of randomized controlled trials, results remained unchanged in ALF, but no differences in survival were found between PE and SMT in ACLF. In conclusion, PE is associated with improved survival in ALF and could improve survival in ACLF. PE may be considered in managing ALF and ACLF patients who are not liver transplant (LT) candidates or as a bridge to LT in otherwise eligible patients. Further randomized controlled trials are needed to confirm the survival benefit of PE in ACLF.
Next-Generation Bone Stimulation: Doubling Down on Bone Anabolics
Wijnen, André J. van , Dashti, Parisa , van Wijnen, Andre J

Journal of Bone and Joint Surgery | August 2, 2023 | Volume: 105 | Issue: 15 | Pages: e38

10.2106/jbjs.23.00550 | PMID 37530724 Get It

Recent Advances in Temporomandibular Joint Surgery
Wroclawski, Catherine, Mediratta, Jai Kumar , Fillmore, W. Jonathan

Medicina | August 2, 2023 | Volume: 59 | Issue: 8 | Pages: 1409

10.3390/medicina59081409 | PMID 37629699 Get It

Temporomandibular disorders (TMDs) affect a high percentage of children and adults worldwide. Surgery may be indicated in severe or recalcitrant cases. Several recent advancements in TMD and temporomandibular joint (TMJ) surgery have elevated understanding and the ability to treat affected patients. We discuss recent advances in TMD epidemiology, juvenile idiopathic arthritis (JIA) of the TMJ, and surgical techniques and technologies. Technical advancements have been identified in TMJ arthroscopy, the treatment of TMJ subluxation and dislocation, and extended prosthetic total TMJ reconstruction (eTMJR). Overall, this review provides valuable insights into significant recent advancements in TMJ disorders and their surgical management.
Costs and Resource Utilization of People with Stable Heart Failure and Insomnia: Evidence from a Randomized Trial of Cognitive Behavioral Therapy for Insomnia
Jeon, Sangchoon , Connell, Meghan O’, Jeon, Sangchoon , Conley, Samantha , Hollenbeak, Christopher S. , Yaggi, Henry Klar , Redeker, Nancy S.

Behavioral Sleep Medicine | August 2, 2023 | Volume: 22 | Issue: 3 | Pages: 263-274

10.1080/15402002.2023.2241589 | PMID 37530117 Get It

Anti‐Gephyrin Antibodies: A Novel Specificity in Patients With Systemic Sclerosis and Lower Bowel Dysfunction
McMahan, Zsuzsanna H. , Andrade, Felipe , Perin, Jamie , Zhang, Chengxiu , Hooper, Jody E. , Wigley, Fredrick M. , Rosen, Antony , Pasricha, Pankaj J. , Casciola‐Rosen, Livia , Andrade, Felipe , Casciola-Rosen, Livia , Kulkarni, Subhash

Arthritis & Rheumatology | August 2, 2023 | Volume: 76 | Issue: 1 | Pages: 92-99

10.1002/art.42667 | PMID 37530745 Get It

Objective Autoantibodies are clinically useful in phenotyping patients with systemic sclerosis (SSc). Gastrointestinal (GI) function is regulated by the enteric nervous system (ENS) and commonly impaired in SSc, suggesting that the SSc autoimmune response may target ENS antigens. We sought to identify novel anti‐ENS autoantibodies with an aim to clinically phenotype SSc GI dysfunction. Methods Serum from a patient with SSc with GI dysfunction but without defined SSc‐associated autoantibodies was used for autoantibody discovery. Immunoprecipitations performed with murine myenteric plexus lysates were on‐bead digested, and autoantigens were identified by mass spectrometry. Prevalence was determined, and clinical features associated with novel autoantibodies were evaluated in a SSc cohort using regression analyses. The expression of gephyrin in human GI tract tissue was examined by immunohistochemistry. Results We identified gephyrin as a novel SSc autoantigen. Anti‐gephyrin antibodies were present in 9% of patients with SSc (16/188) and absent in healthy controls (0/46). Anti‐gephyrin antibody–positive patients had higher constipation scores (1.00 vs 0.50, P = 0.02) and were more likely to have severe constipation and severe distention/bloating (46% vs 15 % , P = 0.005; 54% vs 25%, P = 0.023, respectively). Anti‐gephyrin antibody levels were significantly higher among patients with severe constipation (0.04 vs 0.00 ; P = 0.001) and severe distention and bloating (0.03 vs 0.004 ; P = 0.010). Severe constipation was associated with anti‐gephyrin antibodies even in the adjusted model. Importantly, gephyrin was expressed in the ENS, which regulates gut motility. Conclusion Gephyrin is a novel ENS autoantigen that is expressed in human myenteric ganglia. Anti‐gephyrin autoantibodies are associated with the presence and severity of constipation in patients with SSc.
Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study
Ansell, Stephen M. , Bröckelmann, Paul J. , Keudell, Gottfried von , Lee, Hun Ju , Santoro, Armando , Zinzani, Pier Luigi , Cohen, Jonathon B. , Willenbacher, Wolfgang , Wen, Rachael, Akyol, Alev, Mikita-Geoffroy, Joanna, Engert, Andreas , Armand, Philippe , Cohen, Jonathon B , Savage, Kerry J , Jäger, Ulrich , Willenbacher, Wolfgang , Shipp, Margaret Ann , Zinzani, Pier Luigi , Santoro, Armando , Collins, Graham P. , Boer, Jan Paul de , Kuruvilla, John , Savage, Kerry J. , Trněný, Marek

Blood Advances | August 2, 2023 | Volume: 7 | Issue: 20 | Pages: 6266-6274

10.1182/bloodadvances.2023010334 | PMID 37530622 Get It

Abstract Patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) for whom autologous hematopoietic cell transplantation (auto-HCT) had failed experienced frequent and durable responses to nivolumab in the phase 2 CheckMate 205 trial. We present updated results (median follow-up, ∼5 years). Patients with R/R cHL who were brentuximab vedotin (BV)–naive (cohort A), received BV after auto-HCT (cohort B), or received BV before and/or after auto-HCT (cohort C) were administered with nivolumab 3 mg/kg IV every 2 weeks until progression or unacceptable toxicity. Patients in cohort C with complete remission (CR) for 1 year could discontinue nivolumab and resume upon relapse. Among 243 patients (cohort A, n = 63; B, n = 80; and C, n = 100), the objective response rate (ORR) was 71.2% (95% confidence interval [CI], 65.1-76.8); the CR rate was 21.4% (95% CI, 16.4-27.1). Median duration of response, CR, and partial remission were 18.2 (95% CI, 14.7-26.1), 30.3, and 13.5 months, respectively. Median progression-free survival was 15.1 months (95% CI, 11.3-18.5). Median overall survival (OS) was not reached; OS at 5 years was 71.4% (95% CI, 64.8-77.1). In cohort C, all 3 patients who discontinued in CR and were subsequently re-treated achieved objective response. No new or unexpected safety signals were identified. This 5-year follow-up of CheckMate 205 demonstrated favorable OS and confirmed efficacy and safety of nivolumab in R/R cHL after auto-HCT failure. Results suggest patients may discontinue treatment after persistent CR and reinitiate upon progression. This trial was registered at www.clinicaltrials.gov as #NCT02181713.
Accuracy of DOTATATE PET imaging in the preoperative planning of small bowel neuroendocrine tumor resection
Zhang, Chi , Gudmundsdottir, Hallbera , Takahashi, Hiroaki , Day, Courtney N. , Glasgow, Amy E. , Wasif, Nabil , Grotz, Travis E. , Smoot, Rory L. , Truty, Mark J. , Kendrick, Michael L. , Nagorney, David M. , Grotz, Travis E , Truty, Mark, Cleary, Sean, Kendrick, Michael, Nagorney, David, Navin, Patrick, Thiels, Cornelius A , Smoot, Rory L , Gudmundsdottir, Hallbera , Takahashi, Hiroaki , Starlinger, Patrick , Warner, Susanne G. , Cleary, Sean P. , Navin, Patrick J. , Hálfdánarson, Þorvarður R. , Thiels, Cornelius A.

Journal of Surgical Oncology | August 2, 2023 | Volume: 128 | Issue: 7 | Pages: 1072-1079

10.1002/jso.27413 | PMID 37529970 Get It

AbstractBackground and ObjectivesWe assessed the accuracy of preoperative gallium‐68 DOTA‐Tyr3‐octreotate (DOTATATE) positron emission tomography (PET) imaging in estimating multifocality and nodal metastases of small bowel neuroendocrine tumors (sbNETs).MethodsA multicenter analysis was performed on patients with sbNETs who underwent preoperative DOTATATE PET imaging and surgical resection, with manual palpation of the entire length of the small bowel, between January 2016 and August 2022. Preoperative imaging reports and blinded secondary imaging reviews were compared to the final postoperative pathology reports. Descriptive statistics were applied.ResultsOne‐hundred and four patients met inclusion criteria. Pathology showed 53 (51%) patients had multifocal sbNETs and 96 (92%) had nodal metastases. The original preoperative DOTATATE PET imaging identified multifocal sbNET in 28 (27%) patients and lymph node (LN) metastases in 80 (77%) patients. Based on original radiology reports, sensitivity for multifocal sbNET identification was 45%, specificity was 92%, positive predictive value (PPV) was 86%, and negative predictive value (NPV) was 62%. For the identification of LN metastases, sensitivity was 82%, specificity was 88%, PPV was 99%, and NPV was 29%.ConclusionsAlthough DOTATATE PET imaging is specific and relatively accurate, sensitivity and NPV are insufficient to guide surgical planning. Preoperative use should not replace open palpation to identify additional synchronous lesions or to omit regional lymphadenectomy.
Enterprise standardization and convergence of large-volume infusion pump drug libraries
Ubanyionwu, Samuel, Khandekar, Divya, Mara, Kristin C. , Teaford, Hilary R. , Teaford, Hilary, Mara, Kristin C

American Journal of Health-System Pharmacy | August 1, 2023 | Volume: 80 | Issue: 23 | Pages: 1743-1751

10.1093/ajhp/zxad172 | PMID 37527506 Get It

Abstract Purpose With the implementation of a new electronic health record (EHR) system across Mayo Clinic, a project was approved to standardize and converge 9 region-specific large-volume infusion pump (LVP) drug libraries for Baxter SIGMA Spectrum pumps. Summary The objectives of the project were to (1) develop recommendations for identified variances in practice, (2) consolidate regional drug libraries into a converged enterprise library, (3) improve the drug library management process, and (4) maintain or exceed previous Dose Error Reduction System (DERS) compliance for infusions administered. Harmonization efforts with infusion pumps decreased the number of drug libraries maintained, reduced content maintenance time, and increased readiness for smart infusion pump–EHR interoperability. Seven of the 8 regions for which change in DERS compliance was assessed showed improved compliance relative to baseline in the 30-day postwashout period. Furthermore, when comparing pre- and postimplementation DERS compliance, the number of regions meeting the minimum compliance rate of 95% increased from 5 to 6 regions. Conclusion The project improved the drug library management process, allowed for DERS compliance to be accurately compared across regions, and ensured that patients across the enterprise receive the same standard of care with the administration of intravenous medications.